ProfileGDS5678 / 1451951_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 45% 45% 45% 43% 43% 45% 45% 46% 46% 44% 45% 56% 45% 43% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0816645
GSM967853U87-EV human glioblastoma xenograft - Control 23.0382845
GSM967854U87-EV human glioblastoma xenograft - Control 33.0394545
GSM967855U87-EV human glioblastoma xenograft - Control 42.9332743
GSM967856U87-EV human glioblastoma xenograft - Control 52.9429843
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1332945
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1071245
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0786746
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0671746
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0104544
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0458845
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3769856
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0529745
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9837243